· pdf fileabout us 3 caelum biosciences is a clinical stage biotechnology company developing...
TRANSCRIPT
Non-Confidential Overview
October 2017
CAELUMBIOSCIENCES
Forward Looking Statements
2
Statements in this presentation that are not descriptions of historical facts are forward‐looking statements within the meaning of
the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. We have attempted to identify forward‐looking
statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,”
“may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology.
Forward‐looking statements are based on management’s current expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to
differ materially from those currently anticipated are risks relating to: results of research and development activities; uncertainties
relating to preclinical and clinical testing; our growth strategy; our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; our dependence on third party suppliers; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; the early stage of
products under development; our need for substantial funds; government regulation; patent and intellectual property matters; and
competition. We expressly disclaim any obligation or undertaking to update or revise any statements contained herein to reflect
any change in our expectations or any changes in events, conditions or circumstances after the date of this presentation.
About Us
3
Caelum Biosciences is a clinical stage biotechnology company developingtreatments for rare and life-threatening conditions. Caelum’s lead asset,CAEL-101, is a novel pioneering antibody in Phase 1b clinical trials that isbeing developed for patients with Amyloid Light chain (AL) Amyloidosis.
Michael Spector, CEO
Potential Best-in-Class Antibody developed to clear amyloid deposits
Sustained clinically significant organ activity even after a single dose
Well-tolerated with no dose limiting toxicity
Rationally designed antibody clears both human AL λ and κ in preclinical studies
Ph1b ongoing - last patient dosed; expect results 2017
Preparing for Phase 3
Broad protection through IP and Orphan Drug and Biologics exclusivity
CAEL-101 Opportunity Overview in AL Amyloidosis
4
Amyloid Fibrils Formation in Tissue
5
Misfolded protein
AL Amyloidosis patients
Misfolded proteins collect
together
Collection of misfolded
protein creates Amyloid
fibrils
Plasma Cells
Plasma Cells
Produce
Proteins
Normal Protein
Bone
marrow
produce
plasma cell
Bone
Amyloid Fibrils deposit
in tissues
Normal Plasma Protein Cell Production
Mechanism of Amyloid Formation in Tissues
AL Amyloidosis Impact on Organs & Tissue
60%-80% of patients - leads to end-stage kidney
disease
65%-75% of patients - leads to heart failure and high
mortality
20%-45% of patients - peripheral neuropathy leading
to pain, numbness, and weakness
6
5%-35% - Other organs
AL Amyloidosis Opportunity: High Unmet Need and Large
Market Opportunity
7 Source: Kumar et al, Mayo Clinic Proc, 2011 86(1):12-8.
• 1 Year Mortality: 47%
• 5 Year Mortality: 72%
• Median Mortality: 1.5 Years
• Wall Street Analysts estimate a prevalent patient population of 30,000 – 40,000 patients split evenly between the U.S. and EU.
• It is estimated that there are approximately 3,000 – 4,000 new cases of AL amyloidosis annually in the United States, though actual incidence is likely higher as a result of under-diagnosis; a recent epidemiology study is illustrative (see next slide)
• An approved, successful therapy could represent a >$1.5B opportunity
Case Study: Underdiagnosis of AL Amyloidosis in England
8 1Pinney et. al.; Systemic amyloidosis in England: an epidemiological study; BJH 2013
National
Amyloidosis
Centre
Incidence of AL Amyloidosis by region
0 1.000.50
Correct diagnosis following referral appears to be a function of proximity to specialist center: Suggests that AL Amyloidosis may be
widely underdiagnosed
RegionPopulation (in
mm)
Incidence based on
newly diagnosed
caes at NAC1
Incidence
Reference to
London
England 51.4 0.52 71%
1 – East of England 5.7 0.56 77%
2 – East Midlands 4.4 0.47 64%
3 – London 7.7 0.73 100%
4 – Northeast 2.6 0.07 10%
5 – Northwest 6.8 0.35 48%
6 – South Central 4 0.64 88%
7 – Southeast Coast 4.3 0.55 75%
8 – Southwest 5.2 0.47 64%
9 – West Midlands 5.4 0.64 88%
10 – Yorkshire and the
Humber5.2 0.42 58%
Day-1 Day-14
Amyloid fibril suspensions sourced from human postmortem samples were
injected into mice to form amyloidomas. Mice received either no treatment
or 11-1F4 (CAEL-101).
Untreated Mice
CAEL-101
Treated Mice
Day-14Day-1
CAEL-101 expedites the clearance of AL amyloidoma in a
human PDx mouse model
9
CAEL-101: Rationally designed antibody that
clears both ALλ and κ deposits
Source: Hrncic et al, Am J Path 2000
CAEL-101 removes amyloidomas in mice bearing
human ALΚ & λ fibrils
10
1415
14
21
2425
28
4 4
89
17
24
28
0
5
10
15
20
25
30
κ-1 κ-2 λ-1 λ-2 λ-3 λ-4 λ-5
Da
ys U
nti
l Cle
ara
nce
Single Dose1 3
Untreated 11-1F4
Notes: Days until clearance of untreated vs 11-1F4 treated human amyloidoma deposits injected subcutaneously into mice
1. 100μg at day 0 2. 100 μg at days 0,2,4,6 . 11-1F4 are mAb designation
Source: Hrncic et al, Am J Path 2000
NT NT NT
24
2625
28
NT NT NT
9 9
67
0
5
10
15
20
25
30
κ-1 κ-2 λ-1 λ-2 λ-3 λ-4 λ-5
Da
ys U
nti
l Cle
ara
nce
Multiple Doses2 3
Untreated 11-1F4
CAEL-101-Mediated Clearance of Human ALκ and ALλ Amyloidomas in Mice
• GMP-grade amyloid fibril-reactive human IgG1 Fc chimeric mAb CAEL-101 was produced by NCI’s Biological Resource Branch for a Phase 1a/b trial
• Open-label, dose-escalation Phase 1a/b study of CAEL-101 (NCT02245867)
• Patients with relapsed or refractory AL Amyloidosis
• Primary Objective:
• Establish the maximum tolerated dose (up to 500 mg/m2) of CAEL-101
• Secondary Objectives:
• Demonstrate reduction in amyloid burden, as evidenced by decrease in affected organomegaly, and/or improved organ function
• Determine the pharmacokinetics of CAEL-101 when given as a single IV infusion (phase 1a) or as a series of weekly IV infusions (phase 1b)
• To determine the difference between 250mg/m2 and 500mg/m2
• https://clinicaltrials.gov/ct2/show/NCT02245867
Phase 1a/b Study of CAEL-101 (11-1F14) in Patients with AL
Amyloidosis presented at ASH 2016
11
Palladini et al reported a strong correlation
between reduction in amyloid free light chains and
survival in patients treated with front line
chemotherapy. Cardiac morbidity is the major
determinant of survival in these patients generally,
and changes in cardiac function after therapy can
be reliably assessed using the cardiac
biomarker N-terminal natriuretic peptide type B
(NT-proBNP). Changes in amyloid free light chain
and NT-proBNP predicted survival as early as 3
months after treatment initiation.
The international AL amyloidosis expert community is in agreement that the N-terminal fragment of the probrain natriuretic peptide (NT-proBNP) is
analytically validated and clinically qualified as a biomarker for use as a surrogate end point for survival in patients with AL amyloidosis. (G Merlini et al,
Leukemia, 2016)
12
NT-proBNP Associated with Survival in Amyloidosis Patients:
Potential for Surrogate Endpoint
CAEL-101 binds to
Liver and Bone Amyloid
Fibrils
Wall, JS et al. Blood. 2010 Sep 30;116(13):2241-4.
Distribution of CAEL-101 Antibody Binding
13
Radiolabeled
CAEL-101
Wall’s work shows that CAEL-101 successfully binds AL amyloid.
CAEL-101 Phase 1a/1b Organ Response Rates to Date
14
Renal Response Phase 1a & 1b
(n=8)
Cardiac Response Phase
1a & 1b (n=8)
Overall Responders
Best Organ Response
Phase 1a Phase 1b
12 Weeks
4 Weekly Doses
8 Weeks
Single Dose
63%
Responders
70%
Responders
5/8 Patients
7/10 Patients
Responder Stable Progressor
>30% and >300
pg/ml decrease in
NT-proBNP
>30% and >300
pg/ml decrease in
NT-proBNP
63% 25% 12.5%
5/8
2/4 from Phase 1a
3/4 from Phase 1b
Patients
2/8Patients
1/8
Responder Stable Progressor
75% 25% 0%
6/8 Patients
2/4 from Phase 1a
4/4 from Phase 1b
2/8 Patients
>30% decrease in
proteinuria or a
decrease to <0.5
g/24 hours
>25% worsening in
eGFR
PATIENT 3 PROFILE
Refractory λ AL Amyloidosis
Baseline NT-proBNP approx. 13,000 ng/L
Previous treatments: 1
Best Hematologic response to chemotherapy: VGPR
No Organ response to chemotherapy
Persistently elevated NT-proBNP
NYHA Class III
Organ response to CAEL-101
NYHA Class I
NT-proBNP Reduction to below 4,000 ng/L
Cardiac response (NT-proBNP) in a patient during Phase 1a/b clinical trial of
CAEL-101 antibody
15
Marked and Sustained Cardiac Response After Initial Dose
of CAEL-101
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016
NT
pro
-BN
P (n
g/
L)
Started
Phase 1a
CAEL-101 Started
Phase 1b
CAEL-101Wk
4Wk
8
Wk
5
Wk
8
Wk
12
PATIENT 7 PROFILE
Refractory λ AL Amyloidosis
Baseline 24-hr urine protein in mg/24hr: approx. 10,000
Previous treatments: 6
No Organ response to chemotherapy
Persistence of significant proteinuria
Organ response to CAEL-101
24 hour urine protein in mg/24 hr: approx. 3,000
24 hour urine protein in a patient before and during Phase 1a/b clinical
trial of CAEL-101 antibody
16
Marked and Progressive Renal Response After Initial Dose
of CAEL-101
0
2,000
4,000
6,000
8,000
10,000
12,000
Apr-2015 Jul-2015 Oct-2015 Jan-2016 Apr-2016
24
hru
rin
e p
rote
in (m
g/
24
hr)
Started
Phase 1a
CAEL-101Wk
5
Wk
8
Wk
12
Wk
8
Wk
4
Started
Phase 1b
CAEL-101
• Treatment with CAEL-101 is well tolerated and safe
• No drug-related grade 4 or 5 AEs or dose-limiting toxicity up to an MTD of 500mg/m2
• CAEL-101 is clinically efficacious and rapid-acting
• Early and sustained organ response even as a single infusion, or as a weekly infusion for 4 weeks: 70% response after 4 weekly doses
• Cardiac, Renal, GI, Skin and Soft tissue responses observed
• CAEL-101 represents a novel and promising adjunct to the treatment of AL Amyloidosis
• Safely promotes amyloid resolution in 67% of the patients to date
• Leads to improvement in organ function
Summary Clinical Data CAEL-101
17
• Phase1b study in 2017: Awaiting final data report and PK analysis
• Finalize Phase 3 plan and prepare for trial launch
• Strategic Manufacturing Agreement with Patheon Biologics for clinical trial and commercial manufacturing
Next Steps
18
19
Broad exclusivity through IP and regulatory protection
Phase 3 to commence in 2018
Organ activity independent of light chain sub-type
Marked and sustained responses even after a single dose
No dose-limiting toxicity
Promising Phase 1a/1b data; results anticipated in 2017
Pioneering, rationally designed antibody
Strategic cGMP manufacturing agreement in place
Experienced Leadership Team
CAEL-101 Summary
20
Key Leadership
Lindsay Rosenwald, Executive Chairman
Dr. Rosenwald has almost 25 years of experience as a biotechnology entrepreneur, including the founding and recapitalization
of numerous public and private biotechnology and life sciences companies. In addition to serving as Caelum’s Executive
Chairman, Dr. Rosenwald is Chairman, President and CEO of Fortress Biotech, Caelum’s parent company. Dr. Rosenwald is
also a Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC, a life-science focused asset management
firm. Before moving into his current positions, Dr. Rosenwald served as Chairman of Paramount BioCapital, Inc. Dr. Rosenwald
received an M.D. from Temple University School of Medicine and a B.S. in finance from Pennsylvania State University.
Michael Spector, President and Chief Executive Officer
Mr. Spector was named President and Chief Executive Officer of Caelum in January 2017. Previously, Mr. Spector served as
Senior Vice President, Global Commercial Operations at Iroko Pharmaceuticals. Earlier in his career, he spent 15 years at
GlaxoSmithKline in multiple senior management positions, including Vice President and General Manager of GlaxoSmithKline
South Africa, where he led the overall business strategy and was elected to run the South African Pharmaceutical Manufacturers
Association. Mr. Spector holds an M.B.A. from Rider University in Lawrenceville, N.J. and a B.S. in biology from the University of
Pittsburgh. He also serves on the Board of Directors of Jacaranda Health, a nonprofit organization that seeks to transform
maternal and neonatal healthcare in East Africa.
George Avgerinos, Ph.D. – Senior Vice President, Biologics Operations
Dr. Avgerinos has served as Fortress Biotech’s Senior Vice President, Biologics Operations since June 2013; Caelum Biosciences is a
subsidiary of Fortress Biotech. Dr. Avgerinos joined Fortress from AbbVie Inc., where he was Vice President, HUMIRA® Manufacturing Sciences
and External Partnerships. In his 23 year career at AbbVie, formerly Abbott Laboratories, formerly BASF Bioresearch Corporation (BASF), Dr.
Avgerinos had responsibility for many aspects of Biologics development and operations. These included the HUMIRA® operations franchise,
global biologics process and manufacturing sciences, biologics CMC, manufacturing operations, and third party manufacturing. During his
tenure, Dr. Avgerinos led and participated in the development of numerous clinical candidates which included the launch of HUMIRA®. He
supported expansion of the supply chain to over $9 Billion in annual global sales. Dr. Avgerinos’ efforts on HUMIRA® have been recognized
with numerous awards, including the prestigious Abbott’s Chairman’s award in 2011.Dr. Avgerinos started his career at Biogen, Inc. in 1981
and subsequently joined Collaborative Research Inc. while serving as Adjunct Associate Professor of Chemical Engineering at Tufts University.
Dr. Avgerinos has authored numerous publications in the area of biotechnology product development and manufacturing and holds a number
of product and process patents. Dr. Avgerinos received a B.A. in Biophysics from the University of Connecticut and a Ph.D. in Biochemical
Engineering from the Massachusetts Institute of Technology. Dr. Avgerinos is an employee of Fortress Biotech and provides services to Caelum
Biosciences pursuant to a Management Services Agreement between Fortress Biotech and Caelum Biosciences.
Nova Silver, R.N. – Vice President, Clinical Operations
Ms. Silver has over 20 years of experience in the pharmaceutical industry and since 2011 has served as Vice President, Clinical Operations of
Fortress Biotech, Inc.; Caelum Biosciences is a subsidiary of Fortress Biotech. Prior to joining Fortress and since 2002, Ms. Silver held various
positions at Indevus Pharmaceuticals. While at Indevus, she directly managed and collaborated on multiple pre-clinical and clinical trials for
several investigational drugs with a focus on men’s and women’s health. Most notably she participated in several programs and NDA filings
including the approval and launch of both Sanctura and Sanctura XR (a muscarinic antagonist for the treatment of overactive bladder), Valstar
(bladder cancer), Supprelin/Supprelin LA (central precocious puberty), as well as testosterone undecanoate (hypogonadism) in the US and
Vantas (prostate cancer) in Europe. Ms. Silver was also Endocrine Team Leader for the Clinical Project Transition Team to Endo
Pharmaceuticals during and following its acquisition of Indevus Pharmaceuticals. Prior to joining Indevus, Ms. Silver held a senior research
position at Tufts/New England Medical Center supporting clinical research for multiple pharmaceutical companies and products primarily in
infectious disease. Before embarking on a career in clinical research, Ms. Silver was Faculty at Harvard University in the Department of
Mathematics under Prof. Deborah Hughes Hallett, Cambridge, MA (1994 – 1998) where she was an instructor of algebra, pre-calculus and
calculus to both undergraduate and non-mathematics graduate students. Ms. Silver has her ASN and RN from Regis College/Lawrence
Memorial School of Nursing and BA in both mathematics and economics from Harvard University.
Suzanne Lentzsch, M.D., Ph.D. – Scientific Advisory Board Chair
Professor of Medicine at College of Physicians and Surgeons, Columbia University
Director, Multiple Myeloma and Amyloidosis Service Columbia Univ Medical Center
Dr. Lentzsch is Professor of Medicine and the Director of the Multiple Myeloma and Amyloidosis Service at New York
Presbyterian Hospital/ Columbia University Medical Center, New York. After receiving her degrees from the Humboldt
University/ Charité Berlin, Germany, she completed her residency and fellowship at Humboldt University and a research
fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper
Multiple Myeloma Center under the mentorship of Dr Kenneth Anderson at the Dana-Farber Cancer Institute, Boston. Dr.
Lentzsch was recruited in August 2004 to the University of Pittsburgh and the University of Pittsburgh Cancer Institute. Her
translational research focuses on the identification of novel targets for the treatment of Multiple Myeloma, Multiple
Myeloma bone disease and amyloidosis. Her innovative research in amyloidosis resulted in a series of translational clinical
trials, including the establishment of new treatments for relapsed AL amyloidosis in a multicenter trial investigating
bendamustine.